Beyond the Endpoint: Industry Voices Reflect on Compass’ Phase 3 Readout

This is the second of a two-part series that looks at how people are reacting to Compass Pathways’ first readout from its Phase 3 program of psilocybin for treatment-resistant depression (TRD). (See Compass Pathways’ Psilocybin Clears First Phase 3 Hurdle.) In an earlier article, we shared perspectives from various researchers (see Cautious Optimism, Lingering Questions: Researchers React to…

Source